Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Beats Expectations By $0.08 EPS

Shattuck Labs (NASDAQ:STTK) announced its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08, Briefing.com reports. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs’s revenue was up 2200.0% compared to the same quarter last year.

Shattuck Labs Trading Down 2.9 %

NASDAQ:STTK traded down $0.32 during midday trading on Friday, hitting $10.78. 255,662 shares of the company were exchanged, compared to its average volume of 357,197. The company has a fifty day simple moving average of $9.38 and a 200 day simple moving average of $6.88. Shattuck Labs has a fifty-two week low of $1.33 and a fifty-two week high of $11.62. The company has a market capitalization of $512.59 million, a PE ratio of -5.43 and a beta of 1.98.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Shattuck Labs in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of Shattuck Labs in a report on Friday.

Insider Buying and Selling

In related news, insider Stephen Stout sold 16,004 shares of Shattuck Labs stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total transaction of $168,522.12. Following the sale, the insider now directly owns 74,437 shares in the company, valued at approximately $783,821.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.89% of the stock is owned by company insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.